Request Demo

Last update 08 May 2025

DABIS maleate

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Neoplasms

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC9H18Cl2N2

InChIKeyMOWWNCUQNURBRK-UHFFFAOYSA-N

CAS Registry21787-85-9

View All Structures (2)

100 Clinical Results associated with DABIS maleate

100 Translational Medicine associated with DABIS maleate

100 Patents (Medical) associated with DABIS maleate

Literatures (Medical) associated with DABIS maleate

04 May 2005·JAMA

Heart Risk Rises With Long-term HIV Drugs

Author: Stephenson, Joan

their second day of life. At 6 weeks after delivery, only 4.7% of infants were infected, reported Francois Dabis, MD, of Universite Victor Segalen, in Bordeaux, France. Giving the women a short course of triple therapy after delivery—the Combivir plus the lingering effects of the nevirapine—also helped minimize the development of nevirapine resistance mutations in the women. Overall frequency of resistance mutations in the mothers, determined 4 weeks postpartum, was 1.1% for nevirapine and 8.33% for lamivudine. “This is among the lowest [vertical] transmission rates in Africa, the lowest rate of nevirapine resistance when using single-dose nevirapine, and very low adverse effects,” noted Dabis. “This is very promising for low-income countries,” he said. “Some sites with appropriate infrastructure and training, and where national policies permit, are considering implementing this regimen to reduce resistance,” the Elizabeth Glaser Pediatric AIDS Foundation noted in a statement. “In the meantime, we need to provide women with a range of choices to prevent HIV infection in their infants.” The World Health Organization is considering revising its guidelines on nevirapine use in low-income countries, said Dabis. “The idea is to come up with a menu of options as simple and realistic as possible” to decrease mother-to-child transmission, he said, a menu that could include a singledose nevirapine or a short course of combination therapy to triple-drug combination therapy in settings in which global efforts to expand access to antiretroviral therapy are taking hold. Experts stressed it is essential to keep single-dose nevirapine as an option when other regimens are unavailable. “We need to improve access to better regimens wherever possible,” said McIntyre. For the majority of pregnant women in the developing world who currently have access to nothing, “single-dose nevirapine is a starting point,” he added.

01 Jul 1995·British Journal of CancerQ1 · MEDICINE

CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs

Q1 · MEDICINE

Article

Author: Henrar, R E C. ; Beijnen, J H. ; Flora, K P. ; Slack, J A. ; Halbert, G W.

The pharmaceutical formulation of a new anti-tumour agent has often been perceived as the bottleneck in anti-cancer drug development. In order to increase the speed of this essential development step, the Cancer Research Campaign (CRC), the European Organization for Research and Treatment of Cancer (EORTC) and the National Cancer Institute (NCI) agreed in 1987 to form the Joint Formulation Working Party (JFWP). The main goal of the JFWP is to facilitate the rapid progress of a new drug through pharmaceutical developmental to preclinical toxicology and subsequently to phase I clinical trial. Under the auspices of the JFWP around 50 new agents have been developed or are currently in development. In this report we present our formulation experiences since the establishment of the JFWP with a selected number of agents: aphidicolin glycinate, bryostatin 1, carmethizole, carzelesin, combretastatin A4, dabis maleate, disulphonated aluminium phthalocyanine, E.O.9, 4-hydroxyanisole, pancratistatin, rhizoxin, Springer pro-drug, SRI 62-834, temozolomide, trimelamol and V489. The approaches used and problems presented may be of general interest to scientists in related fields and those considering submitting agents for development.

01 Feb 1993·Biochemical PharmacologyQ2 · MEDICINE

The effects of a benzoic acid mustard derivative of distamycin a (FCE 24517) and related minor groove-binding distamycin analogues on the activity of major groove-binding alkylating agents

Q2 · MEDICINE

Article

Author: Maurizio D'Incalci ; Nicola Mongelli ; Helen M. Coley

The distamycin derivative FCE 24517 is a potent antitumour agent. Efforts have been made towards elucidating the mechanism of action of this compound which, to date, have highlighted a high level of DNA sequence specificity for covalent adduct formation. Compared to classical alkylating agents, FCE 24517 forms very few covalent adducts with double-stranded DNA, and thus appears to be a weak alkylating agent. Examination of the effects of this minor groove-binding agent on the major groove of DNA have been facilitated by use of the alkylating agents mustine, melphalan, dabis maleate, quinacrine mustard and uracil mustard. Pretreatment of plasmid DNA with FCE 24517 followed by reaction with any one of these mustards gave rise to a marked abolition of N-7 guanine adduct formation, as assayed by Maxam and Gilbert sequencing gels. The smallest effect was seen for quinacrine mustard, whereas total abolition of N-7 guanine alkylation was seen with uracil mustard. Using related structural analogues of FCE 24517 in the same experiments, it was not possible to reproduce this effect, with very few exceptions. Some effects were seen when using distamycin A itself in these experiments, although these were marginal compared to those seen for FCE 24517. We were able to extrapolate our findings to a whole cell system using murine L-1210 leukaemia cells. Alkaline elution experiments showed that treatment of cultured cells with FCE 24517 followed by either mustine or uracil mustard caused a marked inhibition of DNA interstrand crosslink formation, compared to treatment with mustine or uracil mustard alone. The present study has demonstrated the marked effect that FCE 24517 has upon the reactivity of double-stranded DNA, an effect possibly separate from that of its alkylating function. This study has highlighted the complex nature of the DNA interactive compound FCE 24517 which possess potent and broad spectrum antitumour activity.

100 Deals associated with DABIS maleate

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 1	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis